C-erbB-2 oncoprotein expression in operable non-small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• The prognostic role of c-erbB-2 oncoprotein in human tumors is debated.
• Assessment criteria for c-erbB-2 expression vary, complicating its use as a prognostic marker.
• Non-small cell lung cancer (NSCLC) prognosis is influenced by multiple factors, but c-erbB-2's specific contribution requires further investigation.

Purpose of the Study:

• To investigate the expression of c-erbB-2 oncoprotein in operable non-small cell lung cancer.
• To evaluate the prognostic significance of c-erbB-2 expression in NSCLC patients treated with surgery.
• To correlate c-erbB-2 expression with clinical and pathological variables.

Main Methods:

• Immunohistochemical staining using NCL-CB11 monoclonal antibody on paraffin-embedded NSCLC sections.
• Analysis focused on cytoplasmic reactivity due to challenges with membrane staining.
• Correlation of c-erbB-2 expression with patient demographics, tumor stage, grade, histology, and proliferation markers (Ki67, p53, EGFR).

Main Results:

• Strong positive cytoplasmic c-erbB-2 staining was observed in 19% of cases, weak in 20%, and negative in 53%.
• c-erbB-2 expression did not correlate with patient age, sex, tumor stage, grade, histology, or proliferation indices.
• Univariate survival analysis showed no statistically significant difference between c-erbB-2 staining groups (p=0.5).

Conclusions:

• T and N-stage were the only statistically significant prognostic variables in this NSCLC cohort.
• c-erbB-2 expression, as assessed by cytoplasmic reactivity, did not demonstrate significant prognostic value in operable NSCLC treated with surgery alone.
• Further studies in specific NSCLC subgroups may be needed to clarify any potential contribution of c-erbB-2 to tumor aggressiveness.